en-Pharma 6 juillet 2015 ABIVAX's IPO to fund HIV and hep B pipeline before potential Big Pharma deal
BioSpace 1 décembre 2014 ABIVAX successfully completes first-in-man study of ABX464, a highly differentiated small molecule targeting HIV
